A Phase-IV, Multicenter, Noncomparative, Open-Label Study Evaluating the Safety and Efficacy of Golimumab (a Fully Human Anti-TNFα Monoclonal Antibody, Administered Subcutaneously) in the Treatment of Indian Patients With Active Spondyloarthropathy of Ankylosing Spondylitis or Psoriatic Arthritis
Latest Information Update: 06 Feb 2025
At a glance
- Drugs Golimumab (Primary)
- Indications Ankylosing spondylitis; Psoriatic arthritis
- Focus Adverse reactions
- Sponsors Johnson & Johnson
Most Recent Events
- 30 Dec 2021 Status changed from active, no longer recruiting to completed.
- 12 Apr 2021 Status changed from recruiting to active, no longer recruiting.
- 19 Feb 2021 Planned primary completion date changed from 25 Jan 2021 to 31 Jan 2022.